Briacell prices shares of $4.7M offering at $3.25 each

Executive Summary

• Briacell Therapeutics Corp. has priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, generating approximately $4.7 million in gross proceeds.
• Net proceeds will be utilized for working capital, general corporate purposes, and the advancement of the company's business objectives.
• ThinkEquity is acting as sole placement agent, with the offering expected to close on June 2, 2026, subject to customary closing conditions.

Key Details

• Offering Structure: Best-efforts offering of common shares
• Quantity: 1,449,300 common shares
• Per-Unit Price: $3.25 per share
• Gross Proceeds: Approximately $4.7 million (before placement agent fees and offering expenses)
• Expected Closing Date: June 2, 2026 (subject to satisfaction of customary closing conditions)
• Use of Proceeds: Working capital requirements, general corporate purposes, and advancement of business objectives
• Placement Agent: ThinkEquity (sole placement agent)
• Regulatory/Exemption: Relies on TSX Section 602.1 exemption for eligible interlisted issuers; sold pursuant to an effective Form S-3 shelf registration statement (File No. 333-276650)
• Prospectus & Distribution: Final prospectus supplement and accompanying prospectus will be filed with the SEC and are accessible via the SEC website or ThinkEquity offices